FDA approves nivolumab for adjuvant Stage IIB/C melanoma treatmentNov 10Regulatory decisionBristol Myers Squibbnivolumab
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Beth Israel registers Phase II lifileucel TIL trial for kidney cancer with IovanceNov 9Trial updatealdesleukinIovance Biotherapeutics, Inc.
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this weekNov 6Weekly roundup, 12 itemsanifrolumab-fniaAstraZenecaUpdated
Nkarta to webcast initial NKX019 data in autoimmune disease at ACR 2026Nov 6PublicationNkarta, Inc.NKX019
Kashiv's Releuko label update approved; Amneal gets cyclophosphamide OK, guaifenesin label changeNov 4Weekly roundup, 3 itemsAmneal Pharmaceuticals, LLCcyclophosphamide
Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Regeneron registers Phase 3 LINKER-AL1 trial of linvoseltamab for AL amyloidosisOct 30Weekly roundup, 6 itemscemiplimab-rwlcdupilumabUpdated
Janssen registers Phase 3 TRIlogy-6 trial in newly diagnosed multiple myelomaOct 30Weekly roundup, 5 itemsbosentandaratumumab
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
AstraZeneca completes balcinrenone/dapagliflozin PK study; posts two new observational trialsOct 23Weekly roundup, 12 itemsabemaciclibAstraZeneca
Merck's KEYNOTE-522 posts results in triple negative breast cancer; new PAH study starts in IndiaOct 22Weekly roundup, 5 itemsMerck & Co., Inc.pembrolizumabUpdated
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Pfizer registers real-world observational study of marstacimab in hemophilia A and B patientsOct 9Weekly roundup, 8 itemsabrocitinibcyclophosphamide
University of Washington trial of Rylaze in adult ALL remains suspended for safety reviewOct 5Clinical readoutasparaginase erwinia chrysanthemi (recombinant)-rywnGenmab A/SUpdated
AbbVie registers Phase 3 trial of etentamig vs Dara-CyBorD in AL amyloidosisAug 28Trial updateAbbViedexamethasone
Roche's glofitamab Phase 2 trial in untreated DLBCL posts results after primary completionAug 18Trial updateglofitamabprednisone
Kite's ZUMA-2 Cohort 3 trial in BTKi-naive mantle cell lymphoma completes, results postedAug 18Trial updatebrexucabtagene autoleucelFludarabine
Cellectar registers Phase 3 trial comparing iopofosine I 131 to R-CD in Waldenstrom'sAug 14Trial updateCellectar Biosciences, Inc.
Nkarta reports Q2 2026 results, continued enrollment in autoimmune NK-cell trialsAug 10Quarterly updateNkarta, Inc.
Nexcella registers Phase 3 NEXICART-3 trial of CAR-T NXC-201 in AL amyloidosisJul 16Trial updateImmix Biopharma, Inc.
Novartis: Mayzent label update approved; four real-world studies registered or recruitingJul 2Weekly roundup, 7 itemsalpelisibFludarabine